News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eleven Biotherapeutics Presents Data on EBI-005, a Novel IL-1 Inhibitor Protein for Topical Treatment of Dry Eye Disease


5/8/2012 10:17:14 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics, announced the presentation of data for EBI-005, the lead drug candidate from Eleven’s AMP-Rx product engine, at the Association for Research in Vision and Ophthalmology (ARVO) 2012 Annual Meeting. Eleven Biotherapeutics researchers presented preclinical data demonstrating optimal properties of EBI-005 for the treatment of dry eye disease (DED), such as high potency, thermal stability and very low systemic exposure. EBI-005, is the first ever rationally-designed, IL-1 (Interleukin-1) receptor inhibitor protein for topical administration that is optimized for the treatment of DED and other ocular surface inflammatory disorders.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES